Download full-text PDF |
Source |
---|
Life Metab
October 2024
CAS Key Laboratory of Nutrition, Metabolism, and Food Safety, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences (CAS), Shanghai 200031, China.
Dyslipidemia affects approximately half of all people with gout, and prior Mendelian randomization analysis suggested a causal role for elevated triglycerides in hyperuricemia (HU), but the underlying mechanisms remain elusive. We hypothesize that dyslipidemia promotes hepatic urate biosynthesis in HU and gout and fatty acid (FA) oxidation (FAO) drives this process. Here we developed a targeted metabolomics to quantify major metabolites in purine metabolic pathway in the sera of a human cohort with HU, gout, and normaluricemic controls.
View Article and Find Full Text PDFAustralas J Ultrasound Med
February 2025
Te Whatu Ora Southern, New Zealand 201 Great King Street, Central Dunedin Dunedin 9016 New Zealand.
Introduction: This case examines the sonographic and clinical challenge of diagnosing a pyogenic liver abscess with systemic metastatic infection.
Case Description: The patient in this case study is an 81-year-old man who presented with intermittent rigors. Following radiological and clinical assessments, a pyogenic liver abscess, with evidence of systemic metastatic infection, was diagnosed.
Ann Surg Oncol
January 2025
Department of Hepatopancreatobiliary and Liver Transplant Surgery, Queen Elizabeth Hospital, Birmingham, United Kingdom.
Ann Clin Biochem
January 2025
Department of Clinical Biochemistry, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, Scotland.
Background: International guidelines give greatly varying definitions of 25-hydroxyvitamin D (25OHD) insufficiency and deficiency. Vitamin D testing is increasing despite 2016 UK guidance for adults advising routine vitamin D supplementation October-March and year-round for high risk groups. A service evaluation of vitamin D testing and biochemical osteomalacia in the North-East of Scotland (57-58°N) could inform definitions and testing guidance.
View Article and Find Full Text PDFBackground: PD-L1 and VEGF blockade with atezolizumab plus bevacizumab has been shown to improve survival in unresectable hepatocellular carcinoma. TIGIT is an immune checkpoint regulator implicated in many cancers, including unresectable hepatocellular carcinoma. Here, we evaluate the clinical activity and safety of the addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab plus bevacizumab.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!